TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05099172: An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation

Sponsor: Bayer · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 430 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$6,558,090

Rescue Site Savings

+$4,319,700

Unlock Full NCT05099172 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05099172 Rescue Dossier →